ClinicalTrials.gg
CompletedNCT02919982BOAT-AFUpdated Jul 27, 2022

Benchmarking an Oral Anticoagulant Treatment Rate in Patients With Nonvalvular Atrial Fibrillation

An observational study in Nonvalvular Atrial Fibrillation, sponsored by Baim Institute for Clinical Research. Completed at 21 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-07-27.

Sponsored by Baim Institute for Clinical Research · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
817
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 993 studies in Atrial Fibrillation with a site in United States — 161 open to participants now, 220 under way, 15 of them phase 3. Atrial Fibrillation · United States.

Enrollment
74th of 308
817 · median 200
Started
2017
with 55 others
Observational
308 of 993
59 open now
Registered
448th of 993
by date

Among the 993 studies in Atrial Fibrillation with a site in United States, this one is the 74th largest by enrollment of the 308 observational ones that give a count, is one of 56 that started in 2017, is one of 308 observational ones, and was the 448th registered.

Atrial Fibrillation

4,009 studies on the registry are indexed under Atrial Fibrillation; 961 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

161 of the 993 studies in Atrial Fibrillation with a site in United States are open now. Recruiting first, the newest first:

156 more — sign in →

All 161 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 993 studies in Atrial Fibrillation with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to establish a benchmark for rate of prescription of oral anticoagulants (OA) in patients with non-valvular atrial fibrillation (NVAF) seen in an ambulatory care setting, based on independent medical assessment of clinical data and physician and patient surveys. The study will also assess reasons for not prescribing OA to prevent thromboembolic complications in patients with NVAF seen in ambulatory care, and patients' perspectives of non-use of OA for treatment of NVAF.

Read the detailed description

At participating centers within the American College of Cardiology's (ACC) PINNACLE Registry, patients with nonvalvular atrial fibrillation who, according to ACC guidelines, are indicated as having an indication for oral anticoagulants (OA), but who are not receiving them, will be identified. Recruitment of participating physicians will also take place through collaboration with the PINNACLE Registry. Physician and patient participants will be asked to complete clinical surveys characterizing use and perception of OA therapy for each individual patient. The Baim Institute for Clinical Research (Baim Institute) serves as an analytic center for the PINNACLE Registry and will collaboratively lead this project with the ACC. The information collected from the PINNACLE Registry will include patient characteristics, site characteristics (volume, region, etc.) and the treating physician characteristics. Information from the patient and physician surveys will provide the clinical reasons for prior nontreatment as assessed by the treating physicians as well as the patients' perception of OA treatment (overall and according to pre-specified subgroups based on patient and site characteristics). Information will also be gathered from the patients' chart.

The above data will be compiled and reviewed by a committee of cardiologists who will assess whether OA treatment would be appropriate based on all the clinical factors assessed.

The BOAT-AF data will be linked to data from the PINNACLE Registry for the patients for whom surveys have been collected. Linking the two datasets will allow assessment of whether or not the participating physicians prescribed OA treatment and whether those patients started OA treatment within approximately 12 months after completing the questionnaire.

03

Conditions studied

  • Nonvalvular Atrial Fibrillation

Browse trials for

Keywords

  • Anticoagulant
  • Nonvalvular atrial fibrillation
  • Registries
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population includes, from participating centers within the PINNACLE Registry, patients with nonvalvular atrial fibrillation identified as having an indication for oral anticoagulants, according to guidelines developed by the American College of Cardiology, but not receiving them.

Eligibility criteria

Inclusion Criteria: A patient must meet all of the following criteria to participate in this study:

  • Able and willing to complete the survey;
  • Diagnosed with nonvalvular atrial fibrillation and CHA2DS2-VASc ≥ 2;
  • Not currently treated with oral anticoagulants according to the PINNACLE Registry data;
  • Enrolled in the PINNACLE Registry;
  • Last physician office visit within the prior 18 months; and
  • Age ≥ 18 years.

Exclusion Criteria: A patient will be excluded from participating in the study for any of the following reasons:

  • Patient is no longer being followed at the local practice;
  • Patient declines participation; and/or
  • Patient is unable to speak or read English.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
817 participants (actual)
Target follow-up
12 Months
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. A benchmark rate of OA treatment in patients with NVAF

    This rate of OA will be based on assessment of appropriateness of OA treatment based on clinical guidelines by cardiologists using clinical data and the physician and patient surveys.

    Time frame: Baseline

Secondary outcomes

  1. Physician Reason for not prescribing OA; Patient perspectives on non-use of OA

    Information from the patient and physician surveys will provide the clinical reasons for prior nontreatment as assessed by the treating physicians as well as the patients' perception of OA treatment (overall and according to pre-specified subgroups based on patient and site characteristics). Information will also be gathered from the patients' charts.

    Time frame: Baseline

Other outcomes

  1. Change in rate of OA use

    Via linking the BOAT-AF data with the PINNACLE Registry data, we will assess if there is a change in the rate of OA one year following the BOAT-AF surveys

    Time frame: 1 year

07

Study locations

21 sites
  • Alaska Heart Institute
    Anchorage, Alaska 95508, United States
  • Orange County Heart Institute and Research Center
    Orange, California 92868, United States
  • Clearwater Cardiovascular & Interventional Consultants MD PA
    Clearwater, Florida 33756, United States
  • Holy Cross Hospital, Inc.
    Fort Lauderdale, Florida 33308, United States
  • Heartwell LLP
    Miami, Florida 33173, United States
  • Cardiac Institute of the Palm Beaches
    Palm Beach Gardens, Florida 33410, United States
  • Adventist Health Partners, Inc. Amita Health
    Hinsdale, Illinois 60521, United States
  • Delmarva Heart LLC
    Salisbury, Maryland 21804, United States
  • Michigan Heart - St. Joseph Mercy Health System
    Ann Arbor, Michigan 48197, United States
  • Munson Medical Group
    Traverse City, Michigan 49684, United States
  • CardioCare, PC
    Hillsborough, New Jersey 08844, United States
  • ProMedica Toledo Hospital
    Toledo, Ohio 43606, United States
  • Southern Oregon Cardiology
    Medford, Oregon 97504, United States
  • Cardiology Consultants of Philadelphia - Lansdale
    Lansdale, Pennsylvania 19446, United States
  • The Heart Institute of East Texas
    Lufkin, Texas 75904, United States
  • Waco Cardiology Associates
    Waco, Texas 20037, United States
  • Revere Health-Heart of Dixie Cardiology Central Utah Clinic PC
    Saint George, Utah 84790, United States
  • Centra Health, Inc. dba Stroobants Cardiovascular Center
    Lynchburg, Virginia 24501, United States
  • Virginia Cardiovascular Specialists
    Richmond, Virginia 23229, United States
  • Western Washington Medical Group, Inc.
    Everett, Washington 98208, United States
  • Kootenai Health dba Heart Clinics of the Northwest
    Spokane, Washington 99204, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2017 to primary completion in May 2018, 16 months.

Of 551 non-industry observational studies under Atrial Fibrillation, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 91. This study's 16 months is below that.

Counting every sponsor, half of 699 studies reached it within 38 months; a quarter within 22 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2016
First posted
Sep 30, 2016
StartActual
Jan 2017
Primary completionActual
May 2018
CompletionActual
Sep 2019
Last update
Jul 27, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02919982
Lead sponsor
Baim Institute for Clinical Research
Collaborators
American College of Cardiology
Responsible party
Sponsor
First posted
Sep 30, 2016
Start date
Jan 2017
Primary completion
May 2018
Completion
Sep 2019
Last update
Jul 27, 2022

Study contacts

Christopher P Cannon, MD
principal investigator · Baim Institute for Clinical Research

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion